Management Team

Oncology Venture has a proven and experienced Management team.

 

Peter Buhl Jensen, Chief Executive Officer, Founder

Buhl Jensen, born 1955, is CEO of Oncology Venture Sweden AB (publ) since 2015, and since 2012, CEO of the wholly owned subsidiary Oncology Venture ApS. Buhl Jensen has a strong combination of commercial experience and expertise in the field of oncology. Buhl Jensen has founded and was previously CEO of TopoTarget A/S. Buhl Jensen was instrumental in TopoTarget’s stock exchange listing in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©. Buhl Jensen is also behind the development of the pharmaceutical drug Belinostat, which was approved by the FDA in the summer of 2014. Buhl Jensen has managerial experience from TopoTarget, where he managed approx. 140 employees and Aalborg Hospital where he was a senior consultant at the Department of Oncology and led approx. 280 employees. Owns 80%* of Buhl Krone Holding ApS** which owns 1,000,000 shares of the Company. Does not hold any warrants in the Company. Member of several boards in Oncology Biotech companies. Since 2010 Chairman of WntResearch.

* The remaining 20% is owned by Ulla Hald Buhl, who is Peter Buhl Jensen’s wife and a member of the Board of Oncology Venture.

** The same corporate registration number as Buhl Oncology ApS

 

SteenKnudsen

Steen Knudsen, Chief Scientific Officer Pre-Clin, Co-Founder and inventor of the Drug Response Prediction method

Knudsen, born 1961, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and as of May 2015, will also be a member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Knudsen is also one of the founders of Oncology Venture ApS, and also co-founder of Medical Prognosis Institute A/S. Knudsen is a Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Furthermore, Knudsen is the inventor of Drug Response Prediction which Oncology Venture has a license from Medical Prognosis Institute A/S. Steen Knudsen represents the majority shareholder, Medical Prognosis Institute A/S. Owns no shares, however holds 5,000 warrants in the Company.

 

4x6-2x2_DanielVonHoff photo 10-2013

Daniel D. Von Hoff, MD, FACD.

In 2012 Oncology Venture and MPI signed an agreement with Dr. Dan Von Hoff to assist Oncology Venture in identifying relevant anticancer drugs that failed to obtain approval by the authorities but where sporadic responses in patients gives hope to the drug if a relevant Drug Response Predictor (DRP™) biomarker can be developed.

Daniel D. Von Hoff, M.D., F.A.C.P.  is Professor of Medicine at the Mayo Clinic and Chief Development Officer at TD2.  He also serves as Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona, as well as Chief Scientific Officer for US Oncology and for Honor Health’s Clinical Research Institute. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ.

Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, nab-paclitaxel and vismodegib. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and former Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

 

Nils Brünner, Scientific adviser, Co-Founder

CEO of WntResearch AB. Professor in Pathobiology and Biomedicine at Faculty of Life Sciences, University of Copenhagen. MD in 1979 and DMSc in 1988. Published more than 300 scientific papers within cancer research with a focus on translational cancer research (H-index 52). 1987-89 post.doc and assistant professor at the National Cancer Institute, Bethesda, MD and Georgetown University, MD, USA. 2003-2006 member of the Board of Directors at EORTC. Has filed several patent applications and serves as medical advisor for a number of biotech companies. Is presently Director of Sino-Danish Breast Cancer Research Centre which is based on a grant from the Danish Natural Science Foundation (Grundforskningsfonden).

 

_MG_0092

Ulla Hald Buhl, Chief Operating Officer, Founder

Hald Buhl, born 1964, is a member of the Board of Directors of Oncology Venture Sweden AB (publ) since 2015, and since March 2015 a member of the Board of Directors of the wholly owned subsidiary Oncology Venture ApS. Hald Buhl has a broad background in clinical trials, organisation management and communications. Hald Buhl has previously been in charge of TopoTarget A/S’s investor relations department and is currently active in this area in both Swedish WNT Research AB (listed on AktieTorget) as well as Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen). During 1999-2001, Hald Buhl worked as a Team Leader in oncology at AstraZeneca A/S and during 2001-2005 Hald Buhl was the head of the regulatory department of TopoTarget A/S. Owns 20%* of Buhl Krone Holding ApS ** which owns 1,000,000 shares of the Company. Holds 5,000 warrants in the Company.

* The remaining 80% is owned by Peter Buhl Jensen, who is Ulla Hald Buhl’s husband and CEO of Oncology Venture.

** The same corporate registration number as Buhl Oncology ApS.

 

Thomas Jensen, Chief Technology Officer

Thomas is pioneering the bridging of: good science, effective laboratory techniques and bioinformatics to advance the biology of cancer. He founded & leads the MPI & OV laboratories in Denmark and in the USA. Along side nurturing our global laboratories, he is instrumental in building our investor relations, securing operational financing and fostering business growth of both MPI and OV.

Amongst Thomas’ accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing.This allows for high resolution analysis of cancer patients’ biopsies. His inventions are an important foundation of the DRP® -Drug Response Prediction platform.

_MG_0118

Nikolaj Buhl Jensen, Chief Financial Officer

Jensen, MSc. Economics, born 1976 is CFO of Oncology Venture Sweden AB (publ) since 2015, and since February 2014, CFO of the wholly owned subsidiary Oncology Venture ApS.

Jensen was instrumental for Oncology Venture’s funding by public funds and private investors during 2014/15 and secured institutional investment from Pre-Seed Innovation (Danish Venture Capital). Jensen was also pivotal for the stock exchange listing on Aktietorget in 2015.

Jensen has previously been teaching at the Copenhagen Business School and has experience from startup’s and private held companies.

 

Annie Rasmussen _HEY14771 (3)

Annie Rasmussen, Chief Clinical Operations

Rasmussen, born 1957, is a member of the management team of Oncology Venture Sweden AB (publ) since 2015. Rasmussen has an extensive experience in clinical oncology 1982 – 1991 and oncology clinical trials organization, management, education and leadership from the University hospital of Copenhagen, Rigshospitalet, Clinical Research Unit involved in EORTC, ECTG and industry phase I and II trials from 1991-1997, SmithKline Beecham, Nordic Oncology Team, marketing and investigator initiated trials 1997-2000 and TopoTarget A/S as head of clinical operations executing more than 20 trials from 2000-2008. Is currently active in clinical operations in Danish Medical Prognosis Institute A/S (listed on NASDAQ First North in Copenhagen) as well as LiPlasome Pharma ApS. Rasmussen founded in 2007 Health Creation Denmark and Cancer Guides DK in 2009.

 

James G. Cullem, J.D., VP Corporate Development

James is a career life sciences entrepreneur and executive who brings 20+ years of diverse experience in the creation, management, and growth of early-stage companies. James is situated in Boston. James has Worked in Oncology Venture Sweden AB (publ) since 2015.

 

Claus Deichgræber, Vice President, Business Development

Worked in Oncology Venture Sweden AB (publ) since 2015. Claus has 25+ years of proven managerial and executive experience throughout Europe, and has headed commercial developments and entrepreneurial start-ups within a variety of industries, in large private- as well as listed companies. Claus has lived, studied and worked abroad for more than a decade, and he fosters new business development possibilities for Oncology Venture in Europe. Claus holds a post-graduate Management Diploma from Henley Business School, and a BA from VIA University College.